Extramedullary plasmacytomas in the head and neck region
- 1.8k Downloads
Extramedullary plasmacytoma (EMP) arises outside the bone marrow, particularly in the head and neck region (nasopharynx, nose cavity, sinuses, and tonsils), and can be associated with multiple myeloma (MM). Three cases of EMP in the head and neck region are described: a first case describes an EMP of the subglottis 3 years after treatment of MM, a second case of an EMP solitary in the middle ear presenting as a jugular foramen syndrome, and a third case of an EMP localised at the epiglottis, recurring at the floor of the nose cavity. Treatment of each EMP was surgical. We reviewed literature about aetiology, clinical course, diagnostics, treatment and prognosis. Important presenting symptoms vary from epistaxis, rhinorrhoea, a sore throat, dysphonia to haemoptoea. Association with MM must be confirmed or excluded. Histopathological examination, with immunological staining or flow cytometry confirms the diagnosis. CT and MRI are useful in staging EMP. The treatment of EMP is surgery and/or radiotherapy. The prognosis depends on tumour size (>5 cm) and nodal involvement. The 10-year survival rate is 50–80%.
KeywordsExtramedullary plasmacytoma Jugular foramen Subglottic Nasal cavity Treatment Prognosis Incidence
Plasmacell disorders are characterised by the accumulation of monoclonal plasmacells that all produce the same immunoglobulin . Plasmacytomas are plasmacell tumours. They can occur solitary outside the bone marrow [solitary bone plasmacytomas (SBP), solitary extramedullary plasmacytomas (EMP)], but can also be associated with multiple myeloma (MM) [2, 3, 4]. EMPs account for 4% of all non-epithelial tumours of the upper respiratory tract . They arise submucosally (80%), in particular at the nasopharynx, nose cavity, sinuses and tonsils.
The median age of presentation of EMP is 55 years and 75% of patients are men; 80% is localised in the head and neck region (nose, sinuses, and nasopharynx). Other localisations are the gastro-intestinal tract, lungs, mammae, testes and skin [6, 7, 8, 9]. The most important presenting symptoms are epistaxis, rhinorrhea, sore throat, dysphonia and haemoptysis [1, 2, 8, 9, 10, 11, 12, 13, 14]. CT and/or MRI is used in monitoring the adhering lymph nodes and bone structures that can also be affected, in particular the nasal cavity and maxillary sinuses . On histopathological investigation, dense plasmacells with a monotone aspect are often present. They possess a round to oval nucleus with a vesicular nuclear chromatin pattern. The nucleus is often located eccentrically in the cytoplasm (perinuclear halo) [15, 16]. Immunohistochemistry and flow cytometry help differentiate EMP from other entities, because EMP is composed of plasmacells that also express CD138 and cytoplasmatic light chains of type κ or λ. Negative stainings for CD20 and positive stainings for CD79 can support this diagnosis. Hotz reported 14 out of 24 patients with EMP in the head and neck region, with a monoclonal lesion after immunohistochemistry. In the other ten patients a reactive polyclonal plasmacytosis was confirmed .
There is an association between different monoclonal gammopathies: MM, monoclonal gammopathy of undetermined significance (MGUS), asymptomatic myeloma (SMM), indolent multiple myeloma (IMM), SBP, Waldenström disease, plasmacell leukaemia, amyloidosis, and heavy chain disorders [17, 18, 19, 20, 21]. Hussong however, recently suggested that EMP represents a form of extranodal marginal lymphoma that has undergone extensive plasmacytic differentiation . In addition to the main plasmacell component, histology also shows characteristics of marginal zone lymphomas: reactive follicles, lymphoepithelial lesions, centrocyt-like cells, and monocytoid cells [10, 15]. Wiltshaw described an association between MM and EMP 25 years ago, but also a predilection for submucosal extension, the incidence of spread to other soft tissues and the rare affection of bone marrow .
The treatment of EMP consists of radiotherapy and/or surgery. The prognosis after radical surgical resection is similar for radiotherapy. In non-radicality, the additional value of radiotherapy is not proven . Many consider the combination of surgery and radiotherapy as treatment of choice.
The next cases describe three patients with plasmacytomas at the ears, nose and throat.
The patient underwent an open tracheotomy and a laryngotracheoscopy with biopsy. Here, a horseshoe-shaped stenosis was observed at the subglottis with a cranial-caudal length of 1.5 cm, a solid consistency and a free anterior border. Biopsies showed superficial atypical inflammatory cells and were not conclusive.
A 72-year-old man, with a medical history of insulin-dependent diabetes and tuberculosis, visited the referring clinic with mastoiditis on the right ear, for which antibiotic treatment was started. Four months later, he again complained of otalgia, with normal otoscopical findings. After an initial expectative management, a facial nerve-paralysis occurred. A prednisolone declining scheme (according to Taverner) and valaciclovir 500 mg three-times daily was started.
An additional serological investigation showed no seroconversion for one of the neurotrope viruses or for Borrelia Burgdorferi. The otalgia persisted and an MRI-scan of the skull base was performed. This showed consolidation of the mastoid cells, consisting with mastoiditis and a higher signal intensity of the sinus sigmoideus. The patient was referred to our institution and underwent a posterior tympanotomy with exploration of the mastoid part of the facial nerve. The covering vessels were visible and no attempt was made for decompression. In the facial recess, tissue was found which impressed as granulation tissue. Frozen biopsy showed reactive connective tissue with a chronic plasmacellular inflammation with no signs of malignancy or malignant lymphoma.
Additional analysis by means of lumbar punction, a skeletal survey and Bence–Jones protein in urine, were all without abnormalities. Post-operative, the headaches disappeared and the facial nerve paresis declined to HB grade II/VI. The foramen jugular syndrome in combination with the effects of radiotherapy however, caused swallowing disorders for which a percutaneous gastrostomy was needed. A year after treatment the patient died of general discomfort.
A 57-year-old man visited a referring clinic with a lesion of the epiglottis suspected for plasmacytoma. An excision biopsy was performed. Histological investigations supported the diagnosis: a dense proliferation of cells with round to oval, eccentric located nuclei and radiated chromatin pattern was seen. Additional immunohistochemical investigation of the tumour cells was positive for CD138 and showed monoclonality for λ light chains.
The patient was referred to our clinic. A lesion of 5 mm was seen at the laryngeal side of the epiglottis. This was microlaryngoscopically excised with laser. Bronchoscopy and esophagoscopy were normal. Immunohistochemical investigations of the removed tissue, showed an inflammatory pseudo-polyp, positive for κ and λ light chains. It concerned a polytypical plasmacell infiltrate. This was not consistent with a suspected rest localisation of plasmacytoma. During outpatient follow-up, 2 months later, the patient complained of haemoptoea. Internal and pulmonary analysis did not show any focus of bleeding or signs of MM, nor an endobronchial lesion. Examination of head and neck did not show any abnormalities in particular at the larynx. However, a round, bowl-shaped tumour was seen at the floor of the nose. A laryngo-, pharyngoscopy and inspection of the mouth was carried out without abnormalities. A subsequent nasendoscopy showed a tumour at the floor of the nose just anterior to the choana, which was excised. Histopathological investigation showed a classic morphology indicating EMP.
Outpatient controls 1 month after the last intervention, showed a new lesion at the left plica ary-epiglottica. Due to the two macroscopically removed plasmacytomas and the clinical suspicion of a new third location, radiotherapy of larynx, hypopharynx and nasopharynx was started with a total dose of 50 Gy. Haematological analysis by means of immunological, laboratory (total IgG, total IgA, total protein urine and protein spectrum), bone marrow aspiration and bone biopsy, showed no signs of MM. Two years after original presentation, this patient is still free of disease.
Criteria EMP 
• Solitary extramedullary mass infiltrated by monoclonal plasmacells
• Absence of morphological and immunophenotypical findings suggestive for reactive plasmacytosis, bad differentiated epithelial tumours, immunoblastic lymphoma and lymphoplasmatic lymphoma
• Normal bone marrow aspiration and biopsy
• Normal results on a radiological skeletal survey and MRI of vertebral column and hip
• No anaemia, hypercalcaemia or kidney disorders caused by a proliferative plasmacell disorder
International Myeloma Working Group 
Criteria symptomatic multiple myeloma
• >10% clonal plasmacells [bone marrow biopsy or elsewhere (plasmacytoma)]
• Monoclonal protein (paraprotein) in serum or urine: >30 g/L
• End-organ damage: hypercalcaemia, renal insufficiency, anaemia, bone lesions (or osteoporosis), frequent infections (>2 per years), amyloidosis elsewhere, hyperviscosity syndrome
Criteria asymptomatic myeloma
• Serum paraprotein >30 g/L and/or
• Clonal plasmacells >10% in bone marrow biopsy and
• No myeloma related organ failure
Criteria monoclonal gammopathy of undetermined significance
• Serum paraprotein <30 g/L and/or
• Clonal plasmacells <10% in bone marrow biopsy and
• No myeloma related organ failure
CT or MRI with technetium contrast can differentiate between inflammatory tissue and/or tumours [24, 25]. Histological investigations by means of light microscopy of the obtained tissue offers differentiation between reactive plasmacytosis, plasmacell granulomas, bad differentiated neoplasms, immunoblastic lymphomas and mucosa-associated lymphomas (MALT) [15, 16]. Differentiation between EMP and MM is important for the prognosis. The treatment is systemic . Besides serum and urine analysis, histochemical peroxidase–anti-peroxidase stainings offer help differentiating EMP and MM. Until now, an approximate 100 cases of EMP are reported in literature [26, 27, 28, 29, 30, 31, 32, 33] of which 25 as metastasis of MM [34, 35, 36, 37]. The diagnosis of laryngeal EMP is difficult because of the non-specific symptoms and the mucosa covering the tumour .
Case 2 concerns a plasmacytoma of the middle ear with extension to the jugular foramen and the temporal bone. The extension to the jugular foramen causes the so-called jugular foramen syndrome (paralysis of the cranial nerves IX, X, XI and eventually XII). The most important processes at the jugular foramen are paraganglioma, schwannoma, meningioma, periferical primitive neuro-ectodermale tumour, chondrosarcoma, chordoma, chondroblastoma, giant-cell tumour, endolymphatic sac tumour cholesterol granuloma, reactive myofibroblastic tumour, temporal bone carcinoma and finally malignant external otitis. Radiologically these processes are diagnosed by means of CT-scan (bone window), MRI and angiography before surgery . Tissue sampling remains necessary. This is not always obvious due to unusual locations of EMP’s.
In Case 3, EMP is recurrent. Independent of the previous location, recurrence occurs. This is important in the follow-up of EMP. About this, no guidelines are available in literature. Additional radiotherapy seems effective. In less than 5% of patients, EMP’s are recurrent. There seems to be a relation between tumour size of >5 cm and the recurrence rate. In nodal affection, this rate is higher. One advises to treat lymph nodes also with radiotherapy . In current literature, no advantages of administration of chemotherapy before or after radiotherapy are found .
In approximately 30% of treated patients distant failure seem to occur. This takes place on average within 2–3 years after diagnosis [6, 7, 8, 9]. Progression is characterised by bone lesions, bone marrow plasmacytosis and high monoclonal protein levels; 15% develops MM, some however develop multiple EMPs without intervening bone marrow plasmacytosis . The most common sites for soft tissue involvement are the lymph node, skin and subcutaneous tissues . Also bone lesions can occur . In MM and SBP, bone involvement is usually within the axial skeleton. In contrast, in EMP, bone lesions seem to be distributed randomly throughout the skeleton . Prognostic variables are hard to clarify due to the small numbers of patients in published series. Adjacent bone destruction may worsen the prognosis in EMP , however this difference has not always been confirmed [8, 14, 40]. There is also a trend of more frequent dissemination of EMP arising outside the head and neck region , for example pulmonary EMP. Most patients die of non-EMP related disorders and more than two-thirds of patients survive for more than 10 years [6, 7, 8, 9].
EMP is a disorder of monoclonal immunoglobulines presenting as plasmacytomas in the head and neck region in particular. Locations are diverse, mostly affecting nose and nasopharynx, but also larynx and mastoid. Prognosis depends on the extension of the EMP and on laboratory findings. Treatment exists of radiotherapy, eventually preceeded by surgery. The prognosis is not unfavourable. Diagnosis and differentiation of other tumours in the head and neck region is important.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
- 7.Brinch L, Hannisdal E, Foss Abrahamsen A, Kvaloy S, Langholm R (1990) Extramedullary plasmacytomas and solitary plasma celltumours of bone. Eur J Haematol 44:131–134Google Scholar
- 8.Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R (1998) Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 441:1063–1067Google Scholar
- 18.Greip PR, San Miguel J, Fonseca R, Avet-Loisau H, Jacobson JL, Rasmussen E, Crowley J, Durie BMG (2003) Development of an international prognostic index (IPI) for myelom: report of the international myeloma working group. Haematol J 4:S42Google Scholar
- 23.Rajkumar SV (2005) Novel approaches to the management of myeloma. Oncolgy 19:621–625Google Scholar